American Journal of Nephrology
Original Report: Patient-Oriented, Translational Research
Increased Levels of Soluble TNF-α Receptors and Cellular Adhesion Molecules in Patients Undergoing Bioincompatible HemodialysisRysz J.a · Majewska E.b · Stolarek R.A.a · Banach M.c · Ciałkowska-Rysz A.d · Baj Z.ea2nd Department of Family Medicine, bDepartment of Pathophysiology and Exercise Immunopathology, cDepartment of Cardiac Surgery, dDepartment of Palliative Medicine, and eDepartment of Pathophysiology and Clinical Immunology, Medical University of Lodz, Lodz, Poland
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: April 26, 2006
Accepted: August 14, 2006
Published online: December 19, 2006
Issue release date: December 2006
Number of Print Pages: 8
Number of Figures: 3
Number of Tables: 1
ISSN: 0250-8095 (Print)
eISSN: 1421-9670 (Online)
For additional information: https://www.karger.com/AJN
Abstract
Background: The study aimed to differentiate the effects of hemodialysis (HD) and chronic renal failure (CRF) on the levels of circulating tumor necrosis factor-α (TNF-α) and TNF-α receptors p55 and p75, soluble vascular cell adhesion molecule-1 (sVCAM-1), intercellular adhesion molecule-1 (sICAM-1), soluble endothelial-leukocyte adhesion molecule-1 (sE-selectin) and sP-selectin in 18 patients on regular HD treatment with cuprophane membrane in relation to 15 non-dialyzed CRF patients and 15 healthy controls. Methods: The serum concentrations were determined with standard ELISA assays. Results: Blood serum p75 and p55 were approximately tenfold increased in CRF (36.7 ± 6.2 and 27.1 ± 5.6 ng/ml) and HD patients (45.6 ± 18.4 and 28.7 ± 5.9 ng/ml) before the HD session (HD 0), during (HD 20) the session (45.7 ± 18.4 and 28.5 ± 7.3 ng/ml) and after (HD 240) the HD session (52.1 ± 17.4 and 30.9 ± 8.2 ng/ml) in comparison to control values (5.6 ± 1.3 and 2.4 ± 0.8 ng/ml, respectively) (p < 0.01). The highest increment of p75 at the end of HD session (HD 240) was also significantly higher than at preceding time points (HD 0 and 20) (p < 0.05). However, the remaining study parameters did not change during an HD session. Also, there were no relevant changes in TNF-α levels if (HD 0) 22.7 ± 21.5 ng/ml and (HD 240) 21.1 ± 18.9 ng/ml were compared. Chronic HD status was related to the increase of sVCAM-1 and sICAM-1 levels. Prior to HD, T0 sVCAM-1 and sICAM-1 concentrations were 2,180.4 ± 761.8 and 567.3 ± 218.8 ng/ml, during HD (T20): 2,172.7 ± 759.2 and 602.3 ± 379.9 ng/ml, and after HD (T240): 2,401.6 ± 756.4 and 648.3 ± 183.5 ng/ml, respectively (p < 0.05 vs. controls and CRF patients). sVCAM-1 and sICAM-1 serum levels (1,262.2 ± 472.9 and 165.6 ± 50.4 ng/ml) were similar in CRF patients and healthy controls (854.4 ± 241.5 and 217.6 ± 74.2 ng/ml, respectively). Even though serum sE- and sP-selectin in CRF patients did not differ from the control (39.8 ± 21.3 vs. 42.1 ± 18.9 ng/ml and 187.9 ± 66.9 vs. 198.8 ± 62.2 ng/ml, respectively), their levels were increased in HD patients up to 111.9 ± 54.6 and 453.2 ± 231.1 ng/ml in patients prior to HD, 118.7 ± 66.2 and 350.8 ± 114.8 ng/ml during the HD session and then 132.3 ± 61.1 and 368.3 ± 126.6 ng/ml, respectively, after its completion (p < 0.05 in comparison with CRF patients and controls). Conclusions: The increased circulating TNF-α receptors appear more associated with the uremic milieu than HD-related systemic inflammation, whereas increased soluble cellular adhesion molecules in patients undergoing bioincompatible HD may be related to the enhanced systemic inflammation specifically due to maintenance HD.
© 2006 S. Karger AG, Basel
Related Articles:
References
-
Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis 1998;32(suppl 5):S112–S119.
External Resources
- Hansson GK: Inflammation, atherosclerosis and coronary artery disease. N Engl J Med 2005;352:1685–1695.
- Rysz J, Banach M, Stolarek RA, Pasnik J, Ciałkowska-Rysz A, Markuszewski L, Baj Z: TNF-alfa priming effect on polymorphonuclear leukocytes reactive oxygen species generation and adhesion molecule expression in hemodialyzed patients. Arch Immunol Ther Exp 2006;54:209–215.
- Stam F, van Guldener C, Schalkwijk CG, ter Wee PM, Donker AJ, Stehouwer CD: Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity. Nephrol Dial Transplant 2003;18:892–898.
- Jacobson SH, Egberg N, Hylander B, Lundahl J: Correlation between soluble markers of endothelial dysfunction in patients with renal failure. Am J Nephrol 2002;22:42–47.
- Bolton CH, Downs LG, Victory JG, Dwight JF, Tomson CR, Mackness MI, Pinkney JH: Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant 2001;16:1189–1197.
- Papagianni A, Kalovoulos M, Kirmizis D, Vainas A, Belechri AM, Alexopoulos E, Memmos D: Carotid atherosclerosis is associated with inflammation and endothelial cell adhesion molecules in chronic hemodialysis patients. Nephrol Dial Transplant 2003;18:113–119.
- Frieling JT, van Hamersvelt HW, Wijdenes J, Hendriks T, Sauerwein RW, van der Linden CJ: Circulating concentrations of soluble interleukin-6 receptors gp80 and gp130 in chronic renal failure and effects of renal replacement therapy. Am J Nephrol 1999;19:571–575.
- Inoue H, Saito I, Nakazawa R, Mukaida N, Matsushima K, Azuma N, Suzuki M, Miyasaka N: Expression of inflammatory cytokines and adhesion molecules in haemodialysis-associated amyloidosis. Nephrol Dial Transplant 1995;10:2077–2082.
- Haran N, Gurwicz S, Gallati H, Shalita B, Bar-Khayim Y: Effect of 1α-hydroxyvitamin D3 treatment on production of tumor necrosis factor-α by peripheral blood mononuclear cells and on serum concentrations of soluble tumor necrosis factor receptors in hemodialysis patients. Nephron 1994;66:262–266.
- Grooteman MP, Nube MJ, Daha MR, Van Limbeek J, van Deuren M, Schoorl M, Bet PM, Van Houte AJ: Cytokine profiles during clinical high-flux dialysis: no evidence for cytokine generation by circulating monocytes. J Am Soc Nephrol 1997;8:1745–1754.
- Van Kuijk WH, Buurman WA, Gerlag PG, Leunissen KM: Vascular reactivity during combined ultrafiltration-hemodialysis: influence of dialysate-derived contaminants. J Am Soc Nephrol 1996;7:2664–2669.
- Papayianni A, Alexopoulos E, Giamalis P, Gionanlis L, Belechri AM, Koukoudis P, Memmos D: Circulating levels of sICAM-1, sVCAM-1, and MCP-1 are increased in haemodialysis patients: association with inflammation, dyslipidaemia, and vascular events. Nephrol Dial Transplant 2002;17:435–441.
- Musial K, Zwolinska D, Polak-Jonkisz D, Berny U, Szprynger K, Szczepanska M: Serum sVCAM-1, sICAM-1, and L-selectin levels in children and young adults with chronic renal failure. Pediatr Nephrol 2005;20:52–55.
- Malyszko J, Malyszko JS, Mysliwiec M: Endothelial cell injury markers in chronic renal failure on conservative treatment and continuous ambulatory peritoneal dialysis. Kidney Blood Press Res 2004;27:71–77.
- Mrowka C, Heintz B, Sieberth HG: Is dialysis membrane type responsible for increased circulating adhesion molecules during chronic hemodialysis? Clin Nephrol 1999;52:312–321.
- Tsirpanlis G, Chatzipanagiotou S, Ioannidis A, Ifanti K, Bagos P, Lagouranis A, Poulopoulou C, Nicolaou C: The effect of viable Chlamydia pneumoniae on serum cytokines and adhesion molecules in hemodialysis patients. Kidney Int Suppl 2003;84:S72–S75.
- Bonomini M, Reale M, Santarelli P, Stuard S, Settefrati N, Albertazzi A: Serum levels of soluble adhesion molecules in chronic renal failure and dialysis patients. Nephron 1998;79:399–407.
- Kahraman S, Yilmaz R, Arici M, Altun B, Erdem Y, Yasavul U, Turgan C: IL-10 genotype predicts serum levels of adhesion molecules, inflammation and atherosclerosis in hemodialysis patients. J Nephrol 2006;19:50–56.
- Papagianni A, Kokolina E, Kalovoulos M, Vainas A, Dimitriadis C, Memmos D: Carotid atherosclerosis is associated with inflammation, malnutrition and intercellular adhesion molecule-1 in patients on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2004;19:1258–1263.
- Peppa M, Uribarri J, Cai W, Lu M, Vlassara H: Glycoxidation and inflammation in renal failure patients. Am J Kidney Dis 2004;43:690–695.
- Cominacini L, Garbin U, Pasini AF, Davoli A, Campagnola M, Contessi GB, Pastorino AM, Lo Cascio V: Antioxidants inhibit the expression of intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 induced by oxidized LDL on human umbilical vein endothelial cells. Free Radic Biol Med 1997;22:117–127.
- Van de Kerkhof J, Schalkwijk CG, Konings CJ, Cheriex EC, van der Sande FM, Scheffer PG, ter Wee PM, Leunissen KM, Kooman JP: N-ε-(carboxymethyl)lysine, N-ε-(carboxyethyl)lysine and vascular cell adhesion molecule-1 (sVCAM-1) in relation to peritoneal glucose prescription and residual renal function: a study in peritoneal dialysis patients. Nephrol Dial Transplant 2004;19:910–916.
- Liakopoulos V, Eleftheriadis T, Kyropoulos T, Voliotis G, Potamianos S, Zengos N, Stefanidis I, Heintz B: Hemodialysis procedure does not affect the levels of sICAM-1 and sVCAM-1 in patients with end-stage renal disease. Ren Fail 2005;27:315–321.
- Zhao S, Zhang Y, Gu Y, Lewis DF, Wang Y: Heme oxygenase-1 mediates up-regulation of adhesion molecule expression induced by peroxynitrite in endothelial cells. J Soc Gynecol Investig 2004;11:465–471.
Article / Publication Details
Received: April 26, 2006
Accepted: August 14, 2006
Published online: December 19, 2006
Issue release date: December 2006
Number of Print Pages: 8
Number of Figures: 3
Number of Tables: 1
ISSN: 0250-8095 (Print)
eISSN: 1421-9670 (Online)
For additional information: https://www.karger.com/AJN
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
